Novo Nordisk A/S (NVO)

NYSE: NVO · IEX Real-Time Price · USD
121.35
+0.12 (0.10%)
At close: Nov 29, 2022 4:00 PM
121.00
-0.35 (-0.29%)
After-hours: Nov 29, 2022 4:28 PM EST
0.1%
Market Cap 270.86B
Revenue (ttm) 21.66B
Net Income (ttm) 6.84B
Shares Out 2.31B
EPS (ttm) 3.24
PE Ratio 37.45
Forward PE 27.86
Dividend $1.60 (1.32%)
Ex-Dividend Date Aug 12, 2022
Volume 2,436,787
Open 121.19
Previous Close 121.23
Day's Range 121.14 - 122.51
52-Week Range 91.51 - 122.51
Beta 0.32
Analysts Buy
Price Target 116.63 (-3.9%)
Earnings Date Nov 2, 2022

About NVO

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a... [Read more]

Industry Pharmaceuticals
Founded 1923
CEO Lars Fruergaard Joergensen
Employees 52,696
Stock Exchange NYSE
Ticker Symbol NVO
Full Company Profile

Financial Performance

In 2021, Novo Nordisk's revenue was 140.80 billion, an increase of 10.91% compared to the previous year's 126.95 billion. Earnings were 47.76 billion, an increase of 13.33%.

Financial numbers in DKK Financial Statements

Analyst Forecast

According to 35 analysts, the average rating for NVO stock is "Buy." The 12-month stock price forecast is 116.63, which is a decrease of -3.89% from the latest price.

Price Target
$116.63
(-3.89% downside)
Analyst Consensus: Buy
Stock Forecasts

News

3 Healthcare Stocks That Could Set You Up For Life

All offer products that are invaluable to their respective audiences.

Other symbols: EXASVEEV
5 days ago - The Motley Fool

Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

Bagsværd , Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a...

1 week ago - GlobeNewsWire

Novo Nordisk A/S – Share repurchase programme

Bagsværd , Denmark, 21 November 202 2 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...

1 week ago - GlobeNewsWire

BAYRY vs. NVO: Which Stock Is the Better Value Option?

BAYRY vs. NVO: Which Stock Is the Better Value Option?

1 week ago - Zacks Investment Research

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 15 November 202 2 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated pers...

2 weeks ago - GlobeNewsWire

Novo Nordisk's Smart Connected Pens Are Now Compatible with Abbott's FreeStyle LibreLink App

GATWICK, England--(BUSINESS WIRE)--This material is intended for UK medical and pharmaceutical trade media only.

2 weeks ago - Business Wire

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd , Denmark, 4 November 2022 – This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...

3 weeks ago - GlobeNewsWire

Novo Nordisk A/S purchases B shares worth DKK 3,582 million from Novo Holdings A/S under the 2022 share repurchase pr...

Bagsværd , Denmark, 04 November 2022 – Today, Novo Nordisk A/S has entered into an agreement to purchase 4,207,500 B shares of DKK 0.20 at a value of DKK 3,582 million from Novo Holdings A/S. The transa...

3 weeks ago - GlobeNewsWire

3 Unstoppable Investments Everyone Needs in Their Portfolio

Not every company can thrive in -- or even survive -- a wobbly economy.

Other symbols: DISSHW
3 weeks ago - The Motley Fool

Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

3 weeks ago - Zacks Investment Research

Novo Nordisk Is Throwing Down The Gauntlet In Weight Loss As Eli Lilly Ramps Up

Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.

3 weeks ago - Investors Business Daily

Novo Nordisk to increase manufacturing capacity of weight-loss drugs

Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.

3 weeks ago - Reuters

Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic

Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit.

3 weeks ago - Reuters

Novo Nordisk lifts guidance as earnings beat expectations

Danish pharmaceutical company Novo Nordisk AS NOVO.B, -2.21% NVO, -2.21% on Wednesday raised full-year guidance and reported a third-quarter net profit that beat expectations amid strong demand for its ...

3 weeks ago - Market Watch

Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 128.9 billion in ...

Financial report for the period 1 January 2022 to 30 September 2022

3 weeks ago - GlobeNewsWire

BAYRY or NVO: Which Is the Better Value Stock Right Now?

BAYRY vs. NVO: Which Stock Is the Better Value Option?

4 weeks ago - Zacks Investment Research

BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor

ISSOIRE, France--(BUSINESS WIRE)-- #digitalhealth--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufact...

1 month ago - Business Wire

Prediction: This Could Be This Company's Next Billion-Dollar Product

It would be a major addition to an already rich portfolio.

1 month ago - The Motley Fool

Novo Nordisk announces the completion of the Forma Therapeutics acquisition

Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed.

Other symbols: FMTX
1 month ago - GlobeNewsWire

Novo Nordisk is ‘a company investors should take a look at,' analyst says

Cowen Vice President Equity Research Michael Nedelcovych joins Yahoo Finance Live to discuss Elon Musk touting a prescription weight-loss drug, the company Novo Nordisk, and U.S. adults living with obes...

1 month ago - Yahoo Finance

7 Stocks for Beginners to Buy Now

The best stocks for beginners in today's stock market can be tough to find and beginners face a steep learning curve. Volatility is high, and bear market conditions ensure that new portfolios will be te...

Other symbols: AAPLAZOKOKRUNP
1 month ago - InvestorPlace

Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?

Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.

1 month ago - Zacks Investment Research

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop...

2 months ago - Business Wire

FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Ad...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forma Therapeutics...

Other symbols: FMTX
2 months ago - Business Wire

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo...

BERKELEY, Calif.--(BUSINESS WIRE)--Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and...

2 months ago - Business Wire